


## EAPB 02303

<b>Cat. No.:</b>	HY-153384
<b>CAS No.:</b>	1958290-51-1
<b>Molecular Formula:</b>	C <sub>17</sub> H <sub>14</sub> N <sub>4</sub> O <sub>2</sub>
<b>Molecular Weight:</b>	306.32
<b>Target:</b>	Microtubule/Tubulin; Apoptosis
<b>Pathway:</b>	Cell Cycle/DNA Damage; Cytoskeleton; Apoptosis
<b>Storage:</b>	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



## SOLVENT & SOLUBILITY

### In Vitro

H<sub>2</sub>O : 30 mg/mL (97.94 mM; ultrasonic and warming and heat to 60°C)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	3.2646 mL	16.3228 mL	32.6456 mL
5 mM	0.6529 mL	3.2646 mL	6.5291 mL
10 mM	0.3265 mL	1.6323 mL	3.2646 mL

Please refer to the solubility information to select the appropriate solvent.

## BIOLOGICAL ACTIVITY

### Description

EAPB 02303 is a microtubule-disrupting agent and inhibitor. EAPB 02303 induces mitosis arrest and impairment of spindle assembly. Thus, EAPB 02303 induces apoptosis and exhibits antitumor activity. EAPB 02303 also exhibits a potent synergy with Paclitaxel (HY-B0015) at lower concentrations<sup>[1]</sup>.

## REFERENCES

[1]. Bigot K, et al. Imiquilines for pancreatic cancer: first-in-class potent and synergistic inhibitors of microtubule polymerisation[J]. Cancer Research, 2023, 83(7\_Supplement): 5729-5729.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA